Literature DB >> 15625612

Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.

Juhani Kahri1, Miia Valkonen, Tom Bäcklund, Matti Vuoristo, Kari T Kivistö.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15625612     DOI： 10.1007/s00228-004-0858-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  16 in total

Review 1.  FDA adverse event reports on statin-associated rhabdomyolysis.

Authors:  Mohamed A Omar; James P Wilson
Journal:  Ann Pharmacother       Date:  2002-02       Impact factor: 3.154

2.  Effect of fluconazole dose on the extent of fluconazole-triazolam interaction.

Authors:  A Varhe; K T Olkkola; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1996-10       Impact factor: 4.335

Review 3.  HMG-CoA reductase inhibitors and myotoxicity.

Authors:  M Ucar; T Mjörndal; R Dahlqvist
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 4.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  Rhabdomyolysis and HMG-CoA reductase inhibitors.

Authors:  M A Omar; J P Wilson; T S Cox
Journal:  Ann Pharmacother       Date:  2001-09       Impact factor: 3.154

7.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Authors:  P J Neuvonen; T Kantola; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  1998-03       Impact factor: 6.875

8.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

9.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

10.  Effect of itraconazole on the pharmacokinetics of atorvastatin.

Authors:  T Kantola; K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1998-07       Impact factor: 6.875
View more
  7 in total

1.  Pharmacology: Dangerous interactions.

Authors:  J E Tebbutt; R M Graham
Journal:  Br Dent J       Date:  2018-11-23       Impact factor: 1.626

2.  Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole.

Authors:  Anne Mette Dybro; Per Damkier; Torsten Bloch Rasmussen; Maja Hellfritzsch
Journal:  BMJ Case Rep       Date:  2016-09-07

3.  Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.

Authors:  E Hoffart; L Ghebreghiorghis; A K Nussler; W E Thasler; T S Weiss; M Schwab; O Burk
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

5.  Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Authors:  Espen Molden; Eva Skovlund; Pia Braathen
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  An observation of impact of neurological consultations in intensive care patients: Case series of 23 patients.

Authors:  Kanwalpreet Sodhi; Rupinder Singh Bhatia; Siddhartha Garg; Anupam Shrivastava
Journal:  Indian J Crit Care Med       Date:  2013-07

7.  Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.

Authors:  Perrine Courlet; Laurent A Decosterd; Susana Alves Saldanha; Matthias Cavassini; Felix Stader; Marcel Stoeckle; Thierry Buclin; Catia Marzolini; Chantal Csajka; Monia Guidi
Journal:  Clin Pharmacokinet       Date:  2020-08       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.